The effect of serotonin(1A) receptor agonism on antipsychotic drug-induced dopamine release in rat striatum and nucleus accumbens

Brain Research

Volumn 858, Issue 2, 2000, Pages 252-263

  Ichikawa, Junji ^a   Meltzer, Herbert Y ^a  

^a Psychopharmacology Div Depts P   (United States)

Author keywords

5 HT(1A) receptor; 5 HT(2A) receptor; Dopamine release; In vivo microdialysis; Nucleus accumbens and striatum; Rat; Typical and atypical antipsychotic drug

Indexed keywords

2 DIPROPYLAMINO 8 HYDROXYTETRALIN; ALPHA (2,3 DIMETHOXYPHENYL) 1 [2 (4 FLUOROPHENYL)ETHYL] 4 PIPERIDINEMETHANOL; AMPEROZIDE; CLOZAPINE; DOPAMINE 2 RECEPTOR BLOCKING AGENT; HALOPERIDOL; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; NEUROLEPTIC AGENT; RISPERIDONE; SEROTONIN 1 AGONIST; SEROTONIN 1A ANTAGONIST; SEROTONIN 1A RECEPTOR; SEROTONIN 2A ANTAGONIST;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE RELEASE; DOSE RESPONSE; IN VITRO STUDY; MALE; MICRODIALYSIS; NONHUMAN; NUCLEUS ACCUMBENS; PRIORITY JOURNAL; RAT; RECEPTOR BINDING;

8-HYDROXY-2-(DI-N-PROPYLAMINO)TETRALIN; ANIMALS; ANTIPSYCHOTIC AGENTS; CLOZAPINE; CORPUS STRIATUM; DOPAMINE; FLUOROBENZENES; HALOPERIDOL; MALE; MICRODIALYSIS; NUCLEUS ACCUMBENS; PIPERAZINES; PIPERIDINES; PYRIDINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, SEROTONIN, 5-HT2A; RECEPTORS, SEROTONIN; RECEPTORS, SEROTONIN, 5-HT1; RISPERIDONE; SEROTONIN; SEROTONIN AGONISTS; SEROTONIN ANTAGONISTS; TRITIUM;

EID: 0034628971     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-8993(99)02346-X     Document Type: Article

References (68)

1. Ahlenius S., Hillegaart V., Wijkstrom A. Evidence for selective inhibition of limbic forebrain dopamine synthesis by 8-OH-DPAT in the rat. Naunyn-Schmiedeberg's Arch. Pharmacol. 339:1989;551-556.
2. 1A receptor selective ligands, (R)-8-OH-DPAT and (S)-UH301, differentially affect the activity of midbrain dopamine neurons. Naunyn-Schmiedeberg's Arch. Pharmacol. 347:1993;353-362.
3. 1A receptor agonist properties of the antipsychotic, nemonapride: comparison with bromerguride and clozapine. Eur. J. Pharmacol. 334:1997;141-147.
4. 1A receptors. Br. J. Pharmacol. 100:1990;793-799.
5. Benloucif S., Galloway M.P. Facilitation of dopamine release in vivo by serotonin agonists: studies with microdialysis. Eur. J. Pharmacol. 200:1991;1-8.
6. Benloucif S., Keegan M.J., Galloway M.P. Serotonin-facilitated release in vivo: pharmacological characterization. J. Pharmacol. Exp. Ther. 265:1993;373-377.
7. 1a receptors in the brain. J. Med. Chem. 32:1989;779-783.
8. Casey D.E. Serotonergic and dopaminergic aspects of neuroleptic-induced extrapyramidal syndromes in nonhuman primates. Psychopharmacology. 112:1993;S55-S59.
9. Chouinard G., Jones B., Remington G., Bloom D., Addington D., MacEwan G.W., Labelle A., Beauclair L., Arnott W. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J. Clin. Psychopharmacol. 13:1993;25-40.
10. Christoffersen C.L., Meltzer L.T. Reversal of haloperidol-induced extrapyramidal side effects in cebus monkeys by 8-hydroxy-2-(di-n-propylamino) tetralin and its enantiomers. Neuropsychopharmacology. 18:1998;399-402.
11. 1A receptors that are negatively coupled to adenylate cyclase. Mol. Pharmacol. 39:1991;780-787.
12. Dajas-Bailador F., Costa G., Emmett S., Bonilla C., Dajas F. Acetylcholinesterase inhibitors block acetylcholine-evoked release of dopamine in rat striatum, in vivo. Brain Res. 722:1996;12-18.
13. Davis K.L., Kahn R.S., Grant K., Davidson M. Dopamine in schizophrenia: a review and reconceptualization. Am. J. Psychiatry. 148:1991;1474-1486.
14. 1A receptor agonists: recent developments and controversial issue. Psychopharmacology. 121:1995;1-26.
15. Drew K.L., O'Connor W.T., Kehr J., Ungerstedt U. Regional specific effects of clozapine and haloperidol on GABA and dopamine release in rat basal ganglia. Eur. J. Pharmacol. 187:1990;385-397.
16. 1A receptor antagonist, WAY100635. Eur. J. Pharmacol. 281:1995;81-88.
17. Golembiowska K., Wedzony K. Enhancement by ipsapirone of dopamine release in the striatum. Pol. J. Pharmacol. 45:1993;299-308.
18. Gurevich E.V., Joyce J.N. Alterations in the cortical serotonergic system in schizophrenia: a postmortem study. Biol. Psychiatry. 42:1997;529-545.
19. Gustafsson B., Christensson E. Amperozide - a new putatively antipsychotic drug with a limbic mode of action on dopamine mediated behaviour. Pharmacol. Toxicol. 66:1990;12-17. Suppl. 1.
20. 1A receptors in prefrontal and temporal cortices of brains from patients with chronic schizophrenia. Life Sci. 48:1991;355-363.
21. Hoffman D.C., Donovan H. Catalepsy as a rodent model for detecting antipsychotic drugs with extrapyramidal side effect liability. Psychopharmacology. 120:1995;128-133.
22. 1 receptors. Eur. J. Pharmacol. 314:1996;285-291.
23. Ichikawa J., Meltzer H.Y. Amperozide, a novel antipsychotic drug, inhibits the ability of D-amphetamine to increase dopamine release in vivo in rat striatum and nucleus accumbens. J. Neurochem. 58:1992;2285-2291.
24. 1A agonist, inhibits amphetamine-induced dopamine release in rat striatum and nucleus accumbens. Eur. J. Pharmacol. 287:1995;179-184.
25. Ichikawa J., Kuroki T., Dai J., Meltzer H.Y. Effect of antipsychotic drugs on extracellular serotonin levels in rat medial prefrontal cortex and nucleus accumbens. Eur. J. Pharmacol. 351:1998;163-171.
26. 1A receptor agonist, potentiated S(-)-sulpiride-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens but not striatum. J. Pharmacol. Exp. Ther. 291:1999;1227-1232.
27. 2A antagonist, potentiates the ability of R(+)-8-OH-DPAT to increase extracellular dopamine (DA-ext) levels in rat medial prefrontal cortex (mPFC). Soc. Neurosci. Abstr. 25:1999;488.9.
28. 1A receptor antagonists, WAY100635 and NDL-249, stimulate locomotion in rats acclimatized to their environment and alter their behaviour: a behavioural analysis. Psychopharmacology. 139:1998;300-310.
29. 1A receptor agonists buspirone, ipsapirone and gepirone are inhibitors of tyrosine hydroxylation in rat striatum. Behav. Brain Res. 73:1996;331-335.
30. 1A autoreceptors of the dorsal and median raphe nuclei. J. Pharmacol. Exp. Ther. 269:1994;1268-1279.
31. 1A receptor agonist, in rat medial prefrontal cortex. Brain Res. 743:1996;357-361.
32. Kuroki T., Meltzer H.Y., Ichikawa J. Effect of antipsychotic drugs on extracellular dopamine levels in rat medial prefrontal cortex and nucleus accumbens. J. Pharmacol. Exp. Ther. 288:1999;774-781.
33. 1A receptors: WAY100635-reversible actions of the highly selective ligands, flesinoxan and S15535. Synapse. 30:1998;172-180.
34. 2 receptors. Psychopharmacology. 112:1993;S40-S54.
35. Lindström E., Eriksson B., Hellgren A., von Knorring L., Eberhard G. Efficacy and safety of risperidone in the long-term treatment of patients with schizophrenia. Clin. Ther. 17:1995;402-412.
36. 2A/C antagonist, reverse haloperidol-induced catalepsy in rats independently of striatal dopamine release. Psychopharmacology. 131:1997;57-63.
37. Marder S.R., Meibach R.C. Risperidone in the treatment of schizophrenia. Am. J. Psychiatry. 151:1994;825-835.
38. 3 receptor mediated dopamine release in the nucleus accumbens during withdrawal from continuous cocaine. Psychopharmacology. 130:1997;242-248.
39. 2 receptor occupancy by typical and atypical antipsychotic drugs in vivo. J. Pharmacol. Exp. Ther. 265:1993;498-508.
40. Meltzer H.Y., Stahl S.M. The dopamine hypothesis of schizophrenia: a review. Schizophr. Bull. 2:1976;19-76.
41. i values. J. Pharmacol. Exp. Ther. 251:1989;238-246.
42. 1A agonist properties: I. Receptorial and neurochemical profile in comparison with clozapine and haloperidol. J. Pharmacol. Exp. Ther. 286:1998;1341-1355.
43. 1A agonist properties: II. Functional profile in comparison with clozapine and haloperidol. J. Pharmacol. Exp. Ther. 286:1998;1356-1373.
44. 2C receptors tonically inhibit dopamine (DA) and noradrenaline (NA), but not 5-HT, release in the frontal cortex in vivo. Neuropharmacology. 37:1998;953-955.
45. 1A receptor agonist flesinoxan in pigeons. Eur. J. Pharmacol. 325:1997;145-153.
46. 35S ]GTPγS binding study Eur. J. Pharmacol. 355:1998;245-256.
47. 1A receptor antagonist (S)-UH301 decreases dopamine release in the rat nucleus accumbens and striatum. J. Neural Transm. 103:1996;541-554.
48. Parada M.A., Hernandez L., De Parada M.P., Murzi E. Selective action of acute systemic clozapine on acetylcholine release in the rat prefrontal cortex by reference to the nucleus accumbens and striatum. J. Pharmacol. Exp. Ther. 281:1997;582-588.
49. G. Paxinos, C. Watson, The Rat Brain in Stereotaxic Coordinates, Academic Press, New York, 1986.
50. Pettersson E. Studies of four novel diphenylbutylpiperazinepyridyl derivatives on release and inhibition of reuptake of dopamine, serotonin and noradrenaline by rat brain in vivo. Eur. J. Pharmacol. 282:1995;131-135.
51. Rada P.V., Mark G.P., Hoebel B.G. In vivo modulation of acetylcholine in the nucleus accumbens of freely moving rats: I. Inhibition by serotonin. Brain Res. 619:1993;98-104.
52. 1a agonist ±8-OH-DPAT modulates basal and stress-induced changes in medial prefrontal cortical dopamine. Synapse. 18:1994;218-224.
53. Schotte A., Janssen P.F.M., Gommeren W., Luyten W.H.M.L., Van Gompel P., Lesage A.S., De Loore K., Leysen J.E. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology. 124:1996;57-73.
54. Seeger T.F., Seymour P.A., Schmidt A.W., Zorn S.H., Schulz D.W., Lebel L.A., McLean S., Guanowsky V., Howard H.R., Lowe J.A., Heym J. Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity. J. Pharmacol. Exp. Ther. 275:1995;101-113.
55. Snyder S.H. Amphetamine psychosis: a "model" schizophrenia mediated by catecholamines. Am. J. Psychiatry. 130:1973;61-67.
56. 2C receptors subtypes in the control of haloperidol-induced release of dopamine in the rat striatum. Soc. Neurosci. Abstr. 24:1998;1087.
57. 2 receptors. J. Pharmacol. Exp. Ther. 266:1993;1374-1384.
58. 1A receptors are increased in postmortem prefrontal cortex in schizophrenia. Brain Res. 708:1996;209-214.
59. 1A agonist tandospirone on memory functions in schizophrenia, J. Clin. Psychopharmacol., in press.
60. 1A receptor activation. Br. J. Pharmacol. 115:1995;703-711.
61. Tanda G., Caroni E., Frau R., Di Chiara G. Increase of extracellular dopamine in the prefrontal cortex: a trait of drugs with antidepressant potential? Psychopharmacology. 115:1994;285-288.
62. Wadenberg M.L., Ahlenius S. Antipsychotic-like profile of combined treatment with raclopride and 8-OH-DPAT in the rat: enhancement of antipsychotic-like effects without catalepsy. J. Neural Transm. 83:1991;43-53.
63. Wadenberg M.L. Serotonergic mechanisms in neuroleptic-induced catalepsy in the rat. Neurosci. Biobehav. Rev. 20:1996;325-339.
64. 2A receptor agonists into the medial prefrontal cortex produces a head-twitch response in rats. J. Pharmacol. Exp. Ther. 282:1997;699-706.
65. 1A receptors. Eur. J. Pharmacol. 149:1988;213-223.
66. Yamada S., Takaki T., Yokoo H., Tanaka M. Inhibitory effect of haloperidol on evoked dopamine release from striatal slices of the rat. Jpn. J. Psychopharmacol. 15:1995;43-52.
67. Yamada S., Takaki T., Yokoo H., Tanaka M. Differential effects of dopamine antagonists on evoked dopamine release from slices of striatum and nucleus accumbens in rats. J. Pharm. Pharmacol. 47:1995;259-262.
68. Zifa E., Fillion G. 5-Hydroxytryptamine receptors. Pharmacol. Rev. 44:1992;401-449.